Tadalafil/tamsulosin - Chong Kun Dang

Drug Profile

Tadalafil/tamsulosin - Chong Kun Dang

Alternative Names: CKD-397; Tamsulosin/tadalafil

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chong Kun Dang
  • Class Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Benign prostatic hyperplasia
  • No development reported Erectile dysfunction

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Erectile-dysfunction(In volunteers) in South Korea (PO, Tablet)
  • 01 Dec 2015 Chong Kun Dang Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (PO) (NCT02645890)
  • 01 Dec 2015 Chong Kun Dang Pharmaceutical plans a phase I trial in Healthy volunteers in South Korea (PO) (NCT02615782)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top